Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01089751 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 322
- Enrollment target
NCT01089751 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 322 participants.
The verdict
NCT01089751, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 322 participants
- Enrollment target
Study Summary
This study will investigate the safety and efficacy of Sanctura XR (trospium chloride) daily in reducing urgency, urinary frequency and urinary urge incontinence in female patients with incontinence refractory to Detrol LA (tolterodine tartrate extended release) 4 mg therapy.
Interventions
- DRUG placebo
- DRUG trospium chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 322 participants |
| Start Date | 2010-03 |
| Est. Completion | 2012-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01089751
The ClinicalTrials.gov registry entry for NCT01089751 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 322 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01089751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01089751 about?
NCT01089751 is a clinical study titled "Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily". This study will investigate the safety and efficacy of Sanctura XR (trospium chloride) daily in reducing urgency, urinary frequency and urinary urge incontinence in female patients with incontinence refractory to Detrol LA (tolterodine tartrate extended release) 4 mg therapy.
What is the current status of trial NCT01089751?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 322 participants. The study started on 2010-03. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01089751?
The interventions under investigation include: placebo (DRUG), trospium chloride (DRUG).
Who is sponsoring clinical trial NCT01089751?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.